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To investigate the relationship between baseline white matter hyperintensities (WMH) in
patients with ischemic stroke and long-term risk of dementia, functional impairment, recurrent
stroke, and mortality.
Methods
Following theMeta-analysis of Observational Studies in Epidemiology and Preferred Reporting
Items for Systematic Reviews and Meta-Analyses guidelines (PROSPERO protocol:
CRD42018092857), we systematically searched Medline and Scopus for cohort studies of
ischemic stroke patients examining whether MRI- or CT-assessed WMH at baseline are as-
sociated with dementia, functional impairment, recurrent stroke, and mortality at 3 months or
later poststroke. We extracted data and evaluated study quality with the Newcastle–Ottawa
scale. We pooled relative risks (RR) for the presence and severity of WMH using random-
effects models.
Results
We included 104 studies with 71,298 ischemic stroke patients. Moderate/severe WMH at
baseline were associated with increased risk of dementia (RR 2.17, 95% confidence interval
[CI] 1.72–2.73), cognitive impairment (RR 2.29, 95% CI 1.48–3.54), functional impairment
(RR 2.21, 95% CI 1.83–2.67), any recurrent stroke (RR 1.65, 95% CI 1.36–2.01), recurrent
ischemic stroke (RR 1.90, 95%CI 1.26–2.88), all-cause mortality (RR 1.72, 95% CI 1.47–2.01),
and cardiovascular mortality (RR 2.02, 95% CI 1.44–2.83). The associations followed dose-
response patterns for WMH severity and were consistent for both MRI- and CT-defined
WMH. The results remained stable in sensitivity analyses adjusting for age, stroke severity, and
cardiovascular risk factors, in analyses of studies scoring high in quality, and in analyses adjusted
for publication bias.
Conclusions
Presence and severity of WMH are associated with substantially increased risk of dementia,
functional impairment, stroke recurrence, and mortality after ischemic stroke. WMH may aid
clinical prognostication and the planning of future clinical trials.
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Whitematter lesions identified as areas of increased signal onT2-
weighted and fluid-attenuated inversion recovery (FLAIR) MRI
sequences or decreased signal on CT (for simplicity, termed
white matter hyperintensities [WMH]) are the most common
imaging feature of cerebral small vessel disease, a major health
problem in aging societies.1–3 The prevalence ofWMH increases
substantially with age4,5 and with the presence of cardiovascular
risk factors.6,7 In population-based cohort studies, WMH were
independently associated with adverse outcomes including
stroke,8,9 dementia,8,9 functional disability,10 and mortality.8,9
WMH are even more common in patients with ischemic stroke
than in the general population.11,12 Brain imaging is recom-
mended in all patients with suspected stroke.13 Hence, precise
knowledge of the prognostic role of WMH may have wide
clinical implications. A growing number of studies suggest that
WMH in ischemic stroke patients are independently associated
with poor outcomes including dementia,14–16 functional
disability,17–19 stroke recurrence,20–22 and death.23–25 However,
the reported results vary between studies possibly because of
small sample size in the majority of studies, variable methodol-
ogy for the assessment of WMH, variable definitions of out-
comes, and different follow-up intervals. Hence, the predictive
role of WMH after ischemic stroke remains to be defined.
Here, leveraging data from published literature, we set out to
explore the long-term prognostic significance of WMH in
patients with ischemic stroke in a systematic review and meta-
analysis. Specifically, we aimed to assess the association between
WMH at the time of the index stroke with long-term risk of
dementia, functional impairment, recurrent stroke, andmortality.
Methods
Standard protocol approvals, registrations,
and patient consent
This systematic review was based on a predefined protocol
(PROSPERO registration number: CRD42018092857) fol-
lowing the Meta-analysis of Observational Studies in Epidemi-
ology (MOOSE) guidelines26 and the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses (PRISMA).27
As all analyses have been based on publicly available summary
statistics and not individual-level data, no ethical approval from
an institutional review board or informed patient consent were
required.
Search strategy
We systematically searched Medline and Scopus from in-
ception through June 1, 2018 (detailed search strategy in
e-Methods, doi.org/10.5061/dryad.8b62gn1), screened Pro-
Quest and OpenGrey as sources of gray literature, and hand-
searched the reference lists of eligible articles and relevant
reviews without language or publication year restrictions. We
evaluated studies for potential population overlap, based on
geographical setting and recruitment period. In case of over-
lap, we included studies presenting the most fully adjusted
model or the ones with the largest sample size. Two authors
(M. Georgakis and M. Duering) performed the literature
search independently, and differences were resolved through
consensus.
Inclusion criteria
We considered eligible all prospective or retrospective cohort
studies that included patients with ischemic stroke and ex-
amining the association of WMH at baseline with the out-
comes of interest over a follow-up period of ≥3 months.
Secondary analyses of randomized controlled trials (RCTs)
examining the same outcomes were also included. Case–
control studies, cross-sectional studies, case reports, case se-
ries of <50 patients, and animal studies were excluded. Our
target population was adult (≥18 years) patients with ische-
mic stroke. Studies examining exclusively patients with hem-
orrhagic stroke and patients with TIA were excluded.
However, we included studies examining mixed populations
of patients with ischemic stroke and TIA or hemorrhagic
stroke, as ischemic stroke patients usually comprise the ma-
jority of participants in these cohorts.
In order to qualify for inclusion into the meta-analysis, WMH
had to be assessed within the first 3 months after the index
stroke event. We included studies assessing WMH by either
MRI or CT, as previous studies have shown substantial
agreement between the 2 methods.28,29 We further included
both studies assessing WMH severity through semi-
quantitative visual rating methods and studies with quantita-
tive measurements of WMH volume.
Our primary outcomes included poststroke dementia, func-
tional impairment, any recurrent stroke, and all-cause mor-
tality, assessed over a period of ≥3 months after stroke.
Dementia had to be defined by standardized criteria (e.g.,
DSM) or validated clinical rating scales (e.g., Clinical De-
mentia Rating scale). Cognitive impairment (mild cognitive
impairment or dementia), defined by formal neuro-
psychological testing or global cognitive tests with validated
cutoffs, was examined as a secondary outcome. Studies ex-
amining performance in specific cognitive domains in con-
tinuous scales were excluded. For functional outcome, we
included studies using tools that have specifically been
Glossary
CI = confidence interval; DSM = Diagnostic and Statistical Manual of Mental Disorders; FLAIR = fluid-attenuated inversion
recovery; ICH = intracerebral hemorrhage; mRS = modified Rankin Scale; NIHSS = NIH Stroke Scale; OR = odds ratio;
RCT = randomized controlled trial; RR = relative risk; WMH = white matter hyperintensities.
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validated to determine disability in the poststroke setting,
such as modified Rankin Scale (mRS), the Oxford Handicap
Scale,30 the Barthel Index,31 and tools assessing functionality
in activities of daily living.32 Functional impairment defined
by a validated cutoff with any of these tools was our primary
outcome, but we also separately examined poor functional
outcome, defined by an mRS score of >2 or >1. Studies not
dichotomizing functional outcome or not providing data
allowing its dichotomization were excluded. For recurrent
stroke, we considered studies assessing any recurrent stroke
(ischemic or hemorrhagic) through imaging or clinical follow-
up or through linkage with disease registries. Recurrent is-
chemic stroke was a secondary outcome. We included studies
assessing all-cause mortality through assessment of death
certificates, linkage with national death registry data, or via
interview with informants during follow-up. Cardiovascular
mortality including death due to ischemic heart disease or
stroke was a secondary outcome.
Quality assessment
We evaluated study quality using the cohort subscale of the
Newcastle–Ottawa scale.33 The following criteria were
assessed: representativeness of exposed cohort, selection of
nonexposed cohort, exposure ascertainment, outcome pres-
ence at study onset, comparability of exposed and unexposed
cohorts, outcome assessment, follow-up length, and follow-up
adequacy. Quality score ranges from 0 to 9 points. Quality
assessment is described in detail in the e-Methods (doi.org/
10.5061/dryad.8b62gn1).
Data extraction
We used a predefined spreadsheet to extract the following
information from each article: study characteristics (geo-
graphical setting, recruitment period, study design); pop-
ulation details (sample size, inclusion/exclusion criteria,
stroke subtypes, age, sex, stroke severity, cardiovascular risk
factors); WMH ascertainment (imaging modality, method
and scale of quantification); outcome assessment (definition,
follow-up timepoint, number of events); and statistical anal-
ysis (type of analysis, relative risk [RR], 95% confidence
intervals [CIs], adjustments). If multiple analysis models were
presented in the individual articles, we extracted the RRs from
the most fully adjusted model. Studies examining cognitive
outcomes, recurrent stroke, and mortality presented hazard
ratios or rate ratios as effect estimates of RR, which were
combined in the same meta-analyses, whereas studies exam-
ining functional outcome presented odds ratios (OR). When
the effect estimate was not directly provided, we calculated
RRs or ORs, respectively, through 2 × 2 tables. To address the
time dependency of cognitive outcomes, recurrent stroke, and
mortality, we also performed sensitivity analyses restricted to
hazard ratios.
Statistical analysis
Our predefined primary analysis approach was a comparison
of moderate/severe vs mild/none WMH, given the high
prevalence of mild WMH alterations in imaging studies of
elderly individuals.4 To harmonize studies using different
WMH rating scales for defining moderate/severe WMH, we
used the definition suggested and validated for each individual
scale. For studies assessing WMH volume and presenting
results in quantiles, we set a cutoff above the median quantile
to define moderate/severe WMH. When studies presented
RRs for >1 WMH severity categories, we obtained the effect
estimate for moderate/severe vs mild/none categories using
the method suggested by Hamling et al.34 We also performed
alternative analyses comparing presence vs absence of WMH
and continuous analyses for increasing WMH severity.
Studies presenting continuous analyses on different severity
scale ranges were harmonized to a 0–3 scale. Studies pre-
senting continuous analyses for WMH volume were analyzed
separately.
To account for the differences across studies regarding WMH
assessment, we pooled the effect sizes of different studies
using random-effects meta-analyses. We set our Bonferroni-
corrected significance threshold to p = 0.05/4 = 0.0125 to
correct for the 4 different primary outcomes. We evaluated
between-study heterogeneity with the I2 and the Cochran Q
statistic; I2 exceeding 50% or 75%was considered as moderate
and high heterogeneity, respectively.35 We evaluated publi-
cation bias using the Egger test (significance threshold set at p
< 0.10),36 and adjusted the pooled effect estimates for pub-
lication bias in a “trim and fill” analysis.37
Sensitivity analyses were performed for the different imaging
modalities (MRI/CT) and WMH quantification methods
(semi-quantitative/volumetry). Additional subgroup analyses
were conducted by study design (prospective/retrospective
and after excluding RCTs), study population (solely ischemic
stroke/ischemic stroke plus TIA or intracerebral hemorrhage
[ICH]), degree of confounder adjustment (age, stroke se-
verity, cardiovascular risk factors), stroke severity (NIH
Stroke Scale [NIHSS] score), age (<70/≥70 years), WMH
location (periventricular/deep), MRI sequence (FLAIR/T2),
follow-up duration (<1/≥1 year), sum quality score, and ful-
fillment of every quality item. In case of heterogeneity, we
examined whether it was explained by any of these factors. We
further conducted meta-regression analysis to evaluate
whether stroke subtypes, age, sex, education, NIHSS score,
atrial fibrillation, hypertension, hypercholesterolemia, di-
abetes mellitus, smoking, stroke history, and coronary artery
disease modified the examined associations.
For studies presenting WMH analyses in ≥3 levels of WMH
severity and adjusting their results at least for age, we con-
ducted dose–response meta-analyses for our primary out-
comes. To assign “doses” to every WMH category, we
harmonized every scale to a 0–3 severity scale (none, mild,
moderate, severe).38 We applied restricted cubic spline
models, using generalized least square regression with pre-
defined knots at 10th, 50th, and 90th percentiles, for in-
dividual studies and thereafter pooled the study-specific
estimates using the restricted maximum likelihood method in
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a random-effects meta-analysis.39 All statistical analyses were
conducted in Stata 13.1 (StataCorp, College Station, TX).
Data availability
The analysis for this study is based on published results from
individual studies. Therefore, individual-level data cannot be
made publicly available. All extracted data from the individual
studies and the code used for performing the meta-analyses




Figure 1 illustrates the study selection process. The litera-
ture search yielded 6,562 articles that were screened for
eligibility. Following evaluation of titles and abstracts, we
examined the full text of 248 articles for eligibility. We
excluded 128 articles that did not meet our eligibility cri-
teria (table e-1, doi.org/10.5061/dryad.8b62gn1) and 16
articles because of overlap with other eligible articles (table
e-2, doi.org/10.5061/dryad.8b62gn1), leaving 104 articles
for inclusion into our systematic review. Thirty-one articles
(n = 16,167 individuals) assessed cognitive outcomes,
49 articles (n = 25,559) assessed functional outcomes,
26 articles (n = 30,256) assessed recurrent stroke, and
28 articles (n = 15,533) assessed mortality.
Study characteristics
The characteristics of studies eventually included in the final
analysis are presented in table e-3 (doi.org/10.5061/dryad.
8b62gn1). Overall, the 104 studies included a total of 71,298
individuals (median sample size n = 266 individuals; minimum
n = 56; maximum n = 9,522). Forty-four studies were retro-
spective cohort studies (n = 20,765), whereas 60 had a pro-
spective design (n = 50,533). Of the latter, 3 studies presented
results from secondary analyses of RCTs (n = 6,637). The
majority of studies (101 out of 104 studies; n = 67,769) were
hospital-based and examined older stroke patients (mean age
≥65 years in 82 studies; n = 62,304). Thirty-eight studies (n =
33,067) included TIA or ICH patients in addition to ischemic
stroke patients, whereas 33 studies (n = 6,278) focused on
specific ischemic stroke subgroups, mainly lacunar stroke or
mild stroke. WMH were assessed solely through MRI in 66
studies (n = 47,963), solely through CT in 31 studies (n =
17,144), and through either method in 7 studies (n = 6,191).
Regarding WMH quantification, 10 studies (n = 7,027) used
volumetry, whereas 77 studies (n = 56,017) rated WMH se-
verity with visual semi-quantitative rating scales, the most
common of which were the Fazekas scale (40 studies; n =
39,776), the Van Swieten scale (15 studies; n = 6,977), and the
age-related white matter changes (ARWMC) scale (15 studies;
n = 8,248). The remaining 17 studies (n = 8,254) assessed
WMH presence only through subjective visual assessment.
Follow-up ranged from 3 months to 15 years with mean
intervals of 38.3months for cognitive outcomes, 5.8months for
functional outcomes, 34.3 months for recurrent stroke, and
33.1 months for mortality.
Study quality
The overall study quality was moderate, with only 7 studies
(7%) fulfilling all quality items assessed by the Newcastle–
Ottawa scale (table e-4, doi.org/10.5061/dryad.8b62gn1).
Median total quality scores for cognitive outcomes, functional
outcomes, recurrent stroke, and mortality were 5/9, 7/9, 7/9,
and 5/8, respectively. Regarding the items on selection bias,
33 studies (32%) lost quality points in representativeness of
the cohort, 17 studies (16%) because of nonvalidated sub-
jective assessment of WMH, and 57 studies (55%) for not
ensuring absence of the outcome at study onset. Furthermore,
38 studies (37%) did not adjust their results for age and 41
studies (39%) did not adjust for cardiovascular risk factors or
stroke severity. Regarding outcome assessment, 16 studies
(52%) did not define dementia or cognitive impairment by
standardized clinical criteria and formal neuropsychological
assessment, 10 studies (38%) did not confirm recurrent stroke
with imaging, and 16 studies (57%) examining mortality did
not cross-link deaths with death certificates. Follow-up in-
terval was considered short (<12 months) for 18 studies
(58%) on cognitive outcome, 6 studies (23%) on recurrent
stroke, and 10 studies (36%) on mortality. Finally, 61 studies
(59%) did not meet the quality criteria for follow-up ade-
quacy, as the attrition rates were >10%.
WMH and outcomes after stroke
We found moderate/severe WMH at baseline (figure 2A) to
be associated with increased risk of dementia (RR 2.17, 95%
CI 1.72–2.73; 12 studies; 12,341 individuals; 2,159 events),
any functional impairment (RR 2.21, 95% CI 1.83–2.67; 25
studies; 16,339 individuals; 6,663 events), any recurrent
stroke (RR 1.65, 95% CI 1.36–2.01; 14 studies; 24,166 indi-
viduals; 3,168 events), and all-cause mortality (RR 1.72, 95%
CI 1.47–2.01; 15 studies; 11,553 individuals; 1,801 events)
after ischemic stroke. Our analyses further showed thatWMH
were associated with all of the examined secondary outcomes
including cognitive impairment (RR 2.29, 95% CI 1.48–3.54;
8 studies; 9,505 individuals; 1,299 events), mRS >1 (RR 1.96,
95% CI 1.67–2.29; 14 studies; 14,155 individuals; 7,350
events), mRS >2 (RR 2.27, 95% CI 1.84–2.81; 19 studies;
13,979 individuals; 5,899 events), recurrent ischemic stroke
(RR 1.90, 95% CI 1.26–2.88; 6 studies; 5,505 individuals; 423
events), and cardiovascular mortality (RR 2.02, 95% CI
1.44–2.83; 5 studies; 2,499 individuals; 621 events).
The analyses examiningWMHpresence vs absence (figure 2B)
andWMH severity in continuous analyses (figure 2C) likewise
showed consistent results for all of the examined primary and
secondary outcomes, except for cardiovascular mortality, where
no studies were available for pooling. Forest plots of the above
results are presented in figures e-1–e-4 (doi.org/10.5061/
dryad.8b62gn1). A meta-analysis of studies examining WMH
volume in linear association with any functional impairment
had similar results (OR per 10 mL increase: 1.29, 95%
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CI 1.10–1.51 and OR per 1 log-WMH volume: 1.20, 95%
CI 1.01–1.44) (figure e-5, doi.org/10.5061/dryad.8b62gn1).
Heterogeneity and sensitivity analyses
We found moderate to high heterogeneity in the moderate/
severe vs mild/none and in the presence vs absence analyses,
but no heterogeneity was noted in the continuous WMH
severity analyses (figure 2). To examine the sources of het-
erogeneity, we performed sensitivity analyses. Our results
remained stable in sensitivity analyses restricted to studies
of prospective or retrospective design, studies including
solely patients with ischemic stroke, studies adjusting for age,
stroke severity, or cardiovascular risk factors, studies of mean
follow-up duration <1 or ≥1 year, studies of higher quality,
studies including patients <70 or ≥70 years and of different
stroke severity, studies evaluating WMH by either MRI or
CT, and in T2 or FLAIR sequences, studies quantifying
WMH by volumetry or semi-quantitative scales, and studies
examining periventricular or deep WMH (figure 3). Our
results further remained stable in sensitivity analyses exclud-
ing studies based on secondary analyses of RCTs (figure e-6,
doi.org/10.5061/dryad.8b62gn1) and when restricting the
analyses to studies presenting hazard ratios as risk estimates
(figure e-7, doi.org/10.5061/dryad.8b62gn1).
Interestingly, sensitivity analyses restricted to studies assess-
ing WMH through FLAIR MRI were not accompanied by
heterogeneity for any of the examined outcomes. Also,
Figure 1 Flowchart on the selection of eligible articles
SVD = small vessel disease; WMH = white matter hyperintensities.
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heterogeneity for dementia, any recurrent stroke, and all-
cause mortality was resolved in analyses restricted to pro-
spective studies, studies restricted to ischemic stroke patients,
and studies adjusting for the maximum number of
confounders. Finally, no heterogeneity was noted for mor-
tality when restricting analyses to studies with a follow-up ≥1
year (figure 3). Sensitivity analyses restricted to studies ful-
filling every Newcastle–Ottawa scale quality criterion also
Figure 2 Associations between white matter hyperintensities (WMH) at baseline and outcomes after stroke
The forest plots depict the summary effect
estimates for the associations of WMH with
cognitive outcomes, functional outcomes, re-
current stroke, and mortality based on 3 dif-
ferent approaches of analyzing WMH severity
([A] moderate/severe vs mild/none WMH; [B]
present vs none WMH; [C] 1 grade increment
[scale 0–3] forWMH [continuous analysis]). CI =
confidence interval; mRS = modified Rankin
Scale; RR = relative risk.
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Figure 3 Subgroup analyses of the association of white matter hyperintensities (WMH) at baseline with stroke outcomes across different study characteristics
The forest plot depicts the summary effect estimates for the associations of WMH, examined as moderate/severe vs mild/none, with dementia, any functional impairment, any recurrent stroke, and all-cause mortality, by
characteristics of the stroke population, neuroimaging methods, and quality factors of the included studies. ARWMC = age-related white matter changes; CI = confidence interval; CVD = cardiovascular disease; FLAIR = fluid-











































showed consistent associations of WMH with all of the
outcomes (table e-5, doi.org/10.5061/dryad.8b62gn1).
Importantly, we found no heterogeneity in analyses for
dementia and recurrent stroke restricted to representative
stroke populations, and to studies ensuring the absence of
prestroke cognitive impairment or history of stroke at
study onset, respectively (table e-5, doi.org/10.5061/
dryad.8b62gn1).
Meta-regression analyses showed that none of the examined
study population characteristics or quality score modified the
associations of WMH with stroke outcomes (table e-6, doi.
org/10.5061/dryad.8b62gn1). However, there was some in-
dication that the effect size of the association between WMH
and dementia increased with an increasing proportion of small
vessel stroke and decreased with an increasing proportion of
cardioembolic stroke within the study population.
Dose–response associations between WMH
and outcomes after stroke
We next examined dose–response associations of WMH se-
verity with stroke outcomes (figure 4). In age-adjusted
dose–response meta-analyses, we found linear associations
between WMH severity and the relative risk for functional
impairment (p for nonlinearity = 0.62; 14 studies; 14,395
individuals; 6,165 events), recurrent stroke (p for nonlinearity
= 0.48; 8 studies; 10,448 individuals; 668 events), and all-
cause mortality (p for nonlinearity = 0.06; 8 studies; 5,763
individuals; 567 events), but a nonlinear association for de-
mentia (p for nonlinearity = 4 × 10−4; 8 studies; 2,149 indi-
viduals; 360 events). More specifically, WMH increased the
risk for dementia only above a moderate WMH severity.
Restricting analyses to studies further adjusting for stroke
severity and cardiovascular risk factors yielded similar results
(figure e-8, doi.org/10.5061/dryad.8b62gn1).
Assessment of publication bias
The Egger test supported presence of small-study effects in-
dicating publication bias in several of the primary analyses
(table e-7 and figure e-9, doi.org/10.5061/dryad.8b62gn1).
Hence, we adjusted our results for publication bias through
a “trim and fill” analysis. Importantly, the effect estimates were
attenuated, but the associations remained in these adjusted
analyses (table e-7, doi.org/10.5061/dryad.8b62gn1).
Figure 4 Dose–response meta-analysis of the age-adjusted association of white matter hyperintensities severity at
baseline with stroke outcomes
The graphs depict the restricted cubic spline derived effect estimates and their 95% confidence intervals (CIs) for (A) dementia, (B) any functional impairment,
(C) any recurrent stroke, and (D) all-cause mortality.
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Discussion
Pooling data from 104 studies including >70,000 ischemic
stroke patients, we found that WMH at the time of stroke are
associated with multiple unfavorable long-term outcomes.
Specifically, we found both the presence and an increasing
severity of WMH to be associated with a higher risk of cog-
nitive impairment and dementia, functional impairment, re-
current stroke, all-cause mortality, and cardiovascular
mortality in follow-up intervals extending up to 15 years after
stroke. The associations followed a dose–response pattern,
with severe WMH being associated with the highest risk for
poor long-term outcomes after stroke. The results were
consistent regardless of imaging modality, were stable in
sensitivity analyses of studies scoring high in quality and of
studies adjusting for age, stroke severity, and cardiovascular
risk factors, and remained after adjustment for publication
bias.
Our findings extend previous literature on the prognostic role
of WMH in the general population.8,9 Stroke marks a high-
risk population amenable to preventive therapies and regular
monitoring. Other than healthy elderly, almost all stroke
patients receive brain imaging as part of their diagnostic
workup.13 WMH can be reliably assessed on routine CT and
MRI scans.28,29,40 As such, our finding of a predictive role of
WMH for multiple long-term outcomes might have wide
clinical implications. Specifically, the assessment of WMH
might aid clinical prognostication, contribute to the in-
terpretation of clinical trials, and possibly also influence
treatment decisions, although this would need to be examined
in controlled trials. To date, there are no treatment options
with proven efficacy for slowing or halting the progression of
WMH lesions. In any case, as WMH influence stroke out-
comes, they should (1) be considered as a confounder for
inclusion in minimization algorithms to balance baseline
characteristics during randomization into trials; (2) be ex-
amined for potential interactions with treatment effect; and
(3) be explored as a prognostic variable in future observa-
tional studies of patients with ischemic stroke.
The mechanisms underlying the associations of WMH with
stroke outcomes are poorly understood. Potential explan-
ations come from the following observations: first, WMH
severity has been associated with infarct growth and larger
infarct volumes in ischemic stroke patients,41–43 suggesting
that the pathologic changes underlying WMH enhance sus-
ceptibility to acute ischemia. Indeed, WMH have been asso-
ciated with both microvascular rarefaction44 and reduced
blood flow45 not only in WMH, but also in normal-appearing
brain tissue. Second, similar to other manifestations of small
vessel disease,46 WMH are a risk factor for symptomatic
intracerebral hemorrhage after ischemic stroke in patients
receiving thrombolysis.19,47 Third, we found that WMH in-
crease the risk for stroke recurrence long-term, which might in
part explain the association between WMH and cognitive
outcome, functional outcome, and mortality. Of note,
however, the stroke recurrence rate observed here was lower
than the incidence rates for these events. Hence, the effects of
WMH on risk of dementia, functional impairment, and
mortality are not sufficiently explained by the effects on stroke
recurrence. Fourth, WMH might influence poststroke out-
comes by disrupting neuronal networks relevant for cognitive
reserve48 and rehabilitation.49 Finally, WMHmight reflect the
systemic burden of vascular risk factors known to influence
stroke outcome,6,7 although the results remained stable in
studies adjusting for these factors.
The identified interaction between ischemic stroke subtype
and the effect of WMH on dementia risk perhaps reflects
fundamental differences in mechanisms of dementia after
different ischemic stroke subtypes. Specifically, we found the
association between WMH burden and poststroke dementia
to be stronger in studies with higher representation of small
vessel stroke. This interaction could relate to aspects of infarct
location involving strategic lesions in subcortical gray or white
matter.50 Nevertheless, these findings are difficult to interpret
in a meta-analysis setting and future original observational
studies are needed to clarify the role of ischemic stroke sub-
types in the examined associations.
This study has several strengths. Our systematic review was
based on a predefined protocol and followed standard
guidelines with rigorous screening of >6,000 articles including
sources of gray literature and without language or publication
year restrictions. Our pooled analysis was based on a large
number of studies examining a wide range of stroke outcomes
in more than 70,000 patients, thus providing robust estimates
for the associations of WMH with dementia, functional im-
pairment, mortality, and recurrent stroke. Finally, extensive
sensitivity and meta-regression analyses enabled us to control
for confounding and other forms of bias.
Our study also has limitations. First, the main analyses
revealed substantial heterogeneity. Potential sources of this
heterogeneity include between-study differences in target
population, study design, assessment and quantification of
WMH, definition and ascertainment of outcomes, follow-up
duration, and statistical approaches. Second, the majority of
studies were of rather lower quality. Specifically, several of the
included studies were not representative of the general stroke
population, showed high attrition rates, did not assess
whether outcomes were present before stroke, and did not
adjust for major confounders such as age, NIHSS, and car-
diovascular risk factors. Third, our analyses suggest marked
publication bias for all outcomes investigated. However, the
associations between WMH and long-term outcomes
remained when adjusting for publication bias. Finally, we
could not examine the influence of the index infarct on the
technical assessment of WMH and whether this affected the
results.
This meta-analysis shows that in patients with ischemic
stroke, both the presence and extent of WMH are associated
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with substantially increased risk of multiple long-term out-
comes including dementia, functional impairment, recurrent
stroke, and mortality. Our findings may have implications for
clinical prognostication and the planning and interpretation of
clinical trials.
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